Tony has co-founded and served as Vice President or President of eight different biotechnology companies. As an executive for these companies, he led four translational programs resulting in clinical trials, including the release into the marketplace of a medical food, SulfzixTM, for heart failure. He has initiated multiple licenses, oversaw build-out of facilities, hired staff and consultants and has raised both dilutive and non-dilutive funding to advance his companies. Tony also has extensive experience in cancer research and development, including work as a Biotechnology Fellow at the NCI, as President and CEO of Alteris, a cancer company acquired by Celldex (NASDAQ: CLDX), and serving as Director of Experimental Therapeutics at Feist-Weiller Cancer Center at LSU Health Shreveport. He also oversaw grant funded research programs at Message Pharmaceuticals and LSU on cancer.
